CPT 0296U mRNA CancerDetect Reimbursement | OpenPayer

Summary & Overview

CPT 0296U: mRNA CancerDetect Saliva NGS Test for Oropharyngeal Cancer

CPT code 0296U identifies Viome Life Sciences Inc.'s mRNA CancerDetect, a Proprietary Laboratory Analyses (PLA) test that uses next-generation sequencing (NGS) of RNA from saliva to detect human and microbial markers and algorithmically report a positive or negative result for oropharyngeal (oral or throat) cancer. As a PLA code, 0296U is specific to a single manufacturer's test and carries implications for laboratory billing, payer coverage policies, and clinical adoption nationwide.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for saliva-based NGS RNA testing, the significance of PLA coding for proprietary assays, and what to expect in payer engagement and coverage policy development. The publication summarizes national-level benchmarks where available, highlights policy and coding considerations tied to PLA codes, and outlines clinical scenarios and typical sites of service for specimen collection and laboratory processing.

This summary is written for a national audience and provides a concise reference on the code's purpose, payer landscape, and the types of operational and policy issues stakeholders should anticipate when managing billing and coverage for 0296U.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0296UCPTProprietary Laboratory AnalysesNGSRNA sequencingsaliva testoropharyngeal cancerlaboratory diagnostics

Billing Code Overview

CPT code 0296U is a Proprietary Laboratory Analyses (PLA) code that describes mRNA CancerDetect from Viome Life Sciences Inc. The test uses next-generation sequencing (NGS) RNA sequencing of human and microbial markers in a saliva specimen with algorithmic analysis to report results as positive or negative for oropharyngeal (oral or throat) cancer.

Service Type: Laboratory diagnostic test using NGS-based RNA sequencing with algorithmic interpretation

Typical Site of Service: Clinical laboratory or other certified laboratory setting that accepts saliva specimens; sample collection may occur in outpatient clinics or designated collection sites

Clinical & Coding Specifications

Clinical Context

A middle-aged adult patient presents to an otolaryngology clinic with persistent throat pain, a non-healing ulcer on the oropharynx, or a new unexplained oral lesion noted during routine dental or primary care exam. The clinician performs a focused head and neck exam and documents risk factors such as tobacco use, heavy alcohol use, prior human papillomavirus (HPV) exposure, or a history of prior head and neck malignancy. When direct visualization or palpation raises concern for early oropharyngeal or oral cancer but immediate biopsy is deferred or the lesion is inaccessible, the clinician orders an mRNA CancerDetect test (0296U) to analyze a saliva specimen via next-generation RNA sequencing.

The clinical workflow typically includes:

Patient counseling and informed consent for a proprietary laboratory test.
Collection of a saliva specimen in the laboratory-specified collection device, labeled and shipped per manufacturer instructions to Viome Life Sciences Inc.
Laboratory processing using RNA extraction and NGS with algorithmic analysis to yield a binary report (positive or negative) for oral/oropharyngeal cancer markers.
Receiving the test report into the electronic health record and integrating results with clinical exam, imaging, and any prior pathology. A positive result prompts expedited diagnostic evaluation (e.g., targeted biopsy, imaging, or referral to head and neck oncology). A negative result may support surveillance when clinical suspicion is low, but decisions are guided by overall clinical context.

Coding Specifications

CPT 0282U: Versiti Red Cell Genotyping Panel, 12-Gene/44-Antigen Analysis

CPT-0180U-NAVIGATOR-ABO-SEQUENCING-BLOOD-GROUP-ANALYSIS

CPT 0180U: Navigator ABO Sequencing Test for ABO Blood Group Antigens

CPT-0021U-APIFINY-PROSTATE-CANCER-AUTOANTIBODY-RISK-SCORE

CPT 0021U: Apifiny® Prostate Cancer Autoantibody Risk Assay

CPT-0368U-COLOSCAPE-CFDNA-QPCR-COLORECTAL-CANCER-RISK

CPT 0368U: ColoScape cfDNA qPCR Panel for Colorectal Cancer Risk

CPT-0031U-CYP1A2-GENOTYPE-MOLECULAR-DIAGNOSTIC

CPT 0031U: Cytochrome P450 1A2 Genotype, Mayo Clinic

CPT-0188U-GERBICH-BLOOD-GROUP-NAVIGATOR-GE-SEQUENCING

CPT 0188U: Gerbich Blood Group Sequencing (Navigator GE)

CPT-0199U-SCIANNA-BLOOD-GROUP-SEQUENCING-NAVIGATOR-SC

CPT 0199U: Scianna Blood Group Sequencing, Navigator SC

CPT-0345U-GENESIGHT-PSYCHOTROPIC-PHARMACOGENOMIC-TEST

CPT 0345U: GeneSight Psychotropic 15-Gene Pharmacogenomic Test

CPT-0259U-GFR-BY-NMR-SERUM-LABTECH-DIAGNOSTICS

CPT 0259U: GFR by NMR Serum Assay, Labtech Diagnostics

CPT-0254U-SMART-PGTA-EMBRYO-ANEUPLOIDY-NGS

CPT 0254U: SMART PGT–A Embryo Aneuploidy Testing with NGS

Showing 1–10 of 536

Taxonomy Code	Specialty	Notes
207M00000X	Otolaryngology	Head and neck surgeons who order diagnostic evaluation and coordinate biopsy or treatment.
207Q00000X	Oral and Maxillofacial Surgery	Surgeons involved when lesions require biopsy or excision.
207L00000X	Dentistry (General Practice)	Dentists who screen oral cavity and refer suspicious findings for further evaluation.
208000000X	Family Medicine	Primary care clinicians ordering noninvasive testing for initial evaluation and risk stratification.
363L00000X	Clinical Laboratory	Laboratory directors and pathologists overseeing test performance and interpretation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C02.9`	Malignant neoplasm of tongue, unspecified	Oral cavity cancers that may shed RNA markers detectable in saliva; indication for molecular testing when clinical suspicion exists.
`C06.9`	Malignant neoplasm of other and unspecified parts of mouth	Lesions in the oral mucosa that warrant noninvasive molecular screening or follow-up testing.
`C09.0`	Malignant neoplasm of tonsillar pillars	Oropharyngeal cancers often assessed with saliva-based molecular assays for detection.
`C10.9`	Malignant neoplasm of oropharynx, unspecified	Primary target diagnosis for the `0296U` mRNA CancerDetect assay.
`R13.0`	Dysphagia, oral phase	Symptom that may prompt evaluation for structural or neoplastic causes, leading to ordering of saliva-based molecular tests.
`R07.81`	Nasopharyngeal mass	Presentation that leads to further diagnostic testing including molecular saliva assays when oropharyngeal involvement is suspected.
`Z12.3`	Encounter for screening for malignant neoplasm of oral cavity	Asymptomatic screening in high-risk individuals where a noninvasive saliva test may be utilized for risk stratification.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87811`	Infectious agent antigen detection by immunoassay with direct optical observation; multiple-step method (e.g., rapid strep)	May be performed in parallel for infectious etiologies of oropharyngeal symptoms but not a substitute for molecular cancer detection; used in differential diagnostic workflows.
`80053`	Comprehensive metabolic panel; 14 tests	Routine laboratory panels often ordered at initial evaluation to assess overall health prior to invasive diagnostics or treatment planning.
`88305`	Level IV surgical pathology, gross and microscopic examination	Used when a targeted oral/oropharyngeal biopsy is obtained following a positive or suspicious `0296U` result; provides histopathologic diagnosis.
`87471`	Infectious agent detection by nucleic acid (e.g., HPV)	HPV testing of oropharyngeal specimens may be ordered alongside cancer evaluation because HPV status is prognostically relevant for oropharyngeal cancers.
`0330U`	Proprietary laboratory test (example PLA)	Other PLA molecular assays may be ordered concurrently for comparative molecular profiling depending on institutional practice; complementary to `0296U` in molecular diagnostic workflows.

`26`	Professional component	When reporting only the professional interpretation component if separate from the laboratory technical component and payer requires split billing.
`TC`	Technical component	When reporting only the technical component (lab processing, sequencing) if separate from the professional component.
`QX`	Service performed by a CRNA with direction by a physician (modifier for Medicare)	Not typically applicable to this lab test; included only when institutional billing rules require modifier reporting for non-physician practitioners involved in specimen handling or interpretation workflows.
`QY`	Medical direction of one CRNA by an anesthesiologist (Medicare)	Not typically used for this test; included from supplied list but rarely applicable.
`52`	Reduced services	When the laboratory performs a reduced or limited version of the assay at reduced complexity or scope compared with the full test.
`53`	Discontinued procedure	When specimen collection or lab processing started but was discontinued for clinical or technical reasons prior to completion.
`76`	Repeat procedure by same physician (not in provided list)	Data not available in the input.
`78`	Unplanned return to the operating/procedure room by same physician following initial procedure (from provided list)	Rarely applicable; may be used institutionally if an associated surgical procedure requires re-entry and billing linkage to the diagnostic testing episode.
`22`	Increased procedural services	If significant additional work or complexity is documented for interpretation beyond standard reporting (rare for PLA tests but used when applicable).
`23`	Unusual anesthesia	Not typically relevant to this noninvasive saliva-based test; included when institutional policy requires reporting for concurrent procedures.

OpenPayer